Article
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
Antiviral therapy - 1 Jan 2014
Izumi Namiki, Yokosuka Osamu, Kawada Norifumi, Osaki Yukio, Yamamoto Kazuhide, Sata Michio, Ishikawa Hiroki, Ueki Tomoko, Hu Wenhua, McPhee Fiona, Hughes Eric A, Kumada Hiromitsu
Abstract excerpt
BACKGROUND: New direct-acting antiviral agents are currently being developed to treat chronic HCV. The efficacy and safety of daclatasvir combined with peginterferon alfa-2a (alfa-2a) and ribavirin were assessed in a randomized, double-blind Phase IIa study of Japanese patients with chronic HCV genotype-1 infection. METHODS: Japanese patients who were treatment-naive (n=25) or prior null (n=12) or partial (n=5)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.